Loading…
Eupraxia Pharmaceuticals Inc. is projected to rise to $9.05 by 2027, a +26% move from its current price of $7.18. EPRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.95 | $7.18 | $7.42 | +0.03% |
| May 30 | $6.86 | $7.18 | $7.53 | +0.07% |
| May 31 | $6.79 | $7.19 | $7.61 | +0.10% |
| Jun 1 | $6.73 | $7.19 | $7.68 | +0.14% |
| Jun 2 | $6.68 | $7.19 | $7.75 | +0.17% |
| Jun 3 | $6.63 | $7.19 | $7.80 | +0.21% |
| Jun 4 | $6.59 | $7.20 | $7.86 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.59 | $7.20 | $7.86 | +0.24% |
| Week 2 | $6.37 | $7.21 | $8.17 | +0.48% |
| Week 3 | $6.21 | $7.23 | $8.42 | +0.72% |
| Week 4 | $6.08 | $7.25 | $8.64 | +0.97% |
| Week 5 | $5.97 | $7.27 | $8.84 | +1.21% |
| Week 6 | $5.88 | $7.28 | $9.03 | +1.45% |
| Week 7 | $5.79 | $7.30 | $9.21 | +1.70% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company that focuses on developing products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract conditions such as eosinophilic esophagitis.
Eupraxia Pharmaceuticals Inc. was incorporated in 2011, is headquartered in Victoria, Canada, and was formerly known as Plaza Capital Partners Inc., changing its name to Eupraxia Pharmaceuticals Inc. in May 2012.
Eupraxia Pharmaceuticals Inc. operates in the Healthcare sector and trades under the symbol EPRX.
The current price is $7.10, and the market cap is $463.82M.
The company ranks 3087 in the market, reflecting its relative size and position. The forecast series suggests an upside price trajectory through 2050, with the 2026 average at $7.10 and the 2050 average at $53.31, supported by bullish long-term sentiment and a path of rising values including a 2040 average of $30.39.
A major floor 23.1% below — a decisive break under it would weaken the trend.
The nearest floor, 12.4% below — buyers have tended to step in here.
The nearest ceiling, 9.9% above — a clean break opens room to run.
A major ceiling 26.3% above — clearing it would confirm fresh momentum.
Key EPRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EPRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.02 | Buy | $7.12 | Buy |
| MA 10 | $6.97 | Buy | $7.08 | Buy |
| MA 20 | $7.25 | Sell | $7.14 | Buy |
| MA 50 | $7.18 | Buy | $7.27 | Sell |
| MA 100 | $7.71 | Sell | $7.25 | Sell |
| MA 200 | $6.81 | Buy | $6.73 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.16 | Neutral |
| Stoch RSI (14) | 75.31 | Neutral |
| CCI (20) | -13.76 | Neutral |
| Williams %R (14) | -32.58 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -3.62 | Sell |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 67.42 | Neutral |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | -0.18 | Sell |
| Ultimate (7,14,28) | 51.57 | Neutral |
| Momentum (10) | -0.43 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 7.36 | Sell |
| ADX (14) | 11.33 | Neutral |
| ATR (14) | 0.24 | Info |
The 30-day technical picture is bullish, with RSI(14) at 50 and a price action context that favors upside activity.
The stock’s 50-day simple moving average sits at $7.18 and the 200-day simple moving average at $6.79, placing the current price near the shorter-term trend while above the longer-term baseline. The 30-day range spans $5.77 to $8.73, with a nearby support at $6.29 and a near-term resistance at $7.89. The annualized volatility stands at 60%, indicating elevated swings within the observed window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.29 | $7.18 | $10.33 | 0% | Neutral | |
| $7.03 | $9.05 | $12.43 | +26% | Bullish | |
| $7.08 | $9.42 | $13.50 | +31% | Bullish | |
| $7.66 | $10.50 | $15.54 | +46% | Bullish | |
| $7.41 | $10.41 | $15.84 | +45% | Bullish | |
| $7.81 | $11.24 | $17.53 | +57% | Bullish | |
| $10.66 | $15.67 | $24.98 | +118% | Bullish | |
| $11.19 | $16.79 | $27.30 | +134% | Bullish | |
| $11.14 | $17.05 | $28.23 | +138% | Bullish | |
| $11.78 | $18.38 | $30.93 | +156% | Bullish | |
| $17.22 | $29.30 | $52.90 | +308% | Bullish | |
| $25.67 | $50.97 | $101.82 | +610% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $6.29 | $7.18 | $8.47 | +0.00% |
| June 2026 | $6.09 | $7.18 | $8.70 | +0.03% |
| July 2026 | $6.21 | $7.41 | $9.12 | +3.15% |
| August 2026 | $6.52 | $7.84 | $9.77 | +5.81% |
| September 2026 | $6.51 | $7.88 | $9.92 | +0.49% |
| October 2026 | $6.35 | $7.72 | $9.81 | -1.95% |
| November 2026 | $6.44 | $7.88 | $10.09 | +2.03% |
| December 2026 | $6.51 | $8.00 | $10.33 | +1.55% |
Click any year to see its month-by-month EPRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EPRX to range from $6.29 to $10.33 through 2026. The $7.18 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The EPRX price prediction for 2027 points to an average of $9.05 (low $7.03, high $12.43) — a potential gain of +26% on today's $7.18. Buyers look set to stay in control over this stretch.
In 2028, EPRX is projected to trade between $7.08 and $13.50, averaging $9.42 — a potential gain of +31% from today's $7.18. That is up +4% on the projected 2027 average. Momentum favours further upside here.
Eupraxia Pharmaceuticals Inc.'s 2029 outlook centres on $10.50, within a $7.66 to $15.54 range. That is up +11% on the projected 2028 average. That marks a +46% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, EPRX could reach as high as $15.84, with a base case around $10.41 and support toward $7.41 — roughly +45% from $7.18. Momentum favours further upside here.
Expect EPRX to range from $7.81 to $17.53 through 2031. The $11.24 average target implies a +57% move from current prices. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The EPRX price prediction for 2032 points to an average of $15.67 (low $10.66, high $24.98) — a potential gain of +118% on today's $7.18. Momentum favours further upside here.
In 2033, EPRX is projected to trade between $11.19 and $27.30, averaging $16.79 — a potential gain of +134% from today's $7.18. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Eupraxia Pharmaceuticals Inc.'s 2034 outlook centres on $17.05, within a $11.14 to $28.23 range. That is up +2% on the projected 2033 average. That marks a +138% change versus current levels. Momentum favours further upside here.
By 2035, EPRX could reach as high as $30.93, with a base case around $18.38 and support toward $11.78 — roughly +156% from $7.18. Buyers look set to stay in control over this stretch.
Expect EPRX to range from $17.22 to $52.90 through 2040. The $29.30 average target implies a +308% move from current prices. That is up +59% on the projected 2035 average. Momentum favours further upside here.
The EPRX price prediction for 2050 points to an average of $50.97 (low $25.67, high $101.82) — a potential gain of +610% on today's $7.18. Buyers look set to stay in control over this stretch.
Investing $1,000 in EPRX today (≈ 139.275766 EPRX) could be worth
$7,099.16
+$6,099.16 (+610%) by 2050 · US Dollar
Based on the average projected EPRX price of $50.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EPRXwould be worth at today's price.
$1,000 invested in EPRX on May 27, 2025 (≈ 259.067365 EPRX) would be worth
$1,860.1
+$860.1 (+86.0%) today · 1.86× · US Dollar
Based on a EPRX entry price of $3.86 vs. today's $7.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.37 | $1,127.16 | +12.7% |
| 1 month ago | $7.21 | $995.84 | -0.4% |
| 3 months ago | $8.18 | $877.75 | -12.2% |
| 6 months ago | $6.21 | $1,156.2 | +15.6% |
| 1 year ago | $3.86 | $1,860.1 | +86.0% |
| All time (2.1y) ago | $2.95 | $2,433.9 | +143.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EPRX forecast.
Our base-case forecast reaches $14.00 around 2032.
Implied market cap at $14.00: $914.58M
2030 forecast shows an average price of $10.55 with a min of $7.59 and a max of $15.85, and an estimated ROI of 48.5% with bullish sentiment.
2040 forecast shows an average price of $30.39 with a min of $18.31 and a max of $53.84, and an estimated ROI of 328.1% with bullish sentiment.
2050 forecast shows an average price of $53.31 with a min of $27.88 and a max of $104.15, and an estimated ROI of 650.9% with bullish sentiment.
These are estimates, not guarantees, and are subject to uncertainty and market conditions.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $10.55 with a min of $7.59 and a max of $15.85; ROI is 48.5% and sentiment is BULLISH.
The longer-term forecast shows bullish sentiment across multiple years, with rising averages and ROI figures (e.g., 2027 avg $8.97, ROI 26.3; 2031 avg $11.64, ROI 64; 2035 avg $18.81, ROI 164.9; 2040 and 2050 also show substantial upside).
Yes. The forecast maximums include $53.84 in 2040 and $104.15 in 2050.
Current price: $7.10. Market cap: $463.82M.
The 30-day range is $5.77 to $8.73.
Eupraxia Pharmaceuticals Inc. Community Discussion
0Share your Eupraxia Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.